|
Cardiovascular Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Further, state-of-the-art approaches, such as antibodies to PCKSK9 (proprotein convertase subtilisin-kexin type 9); RNA therapeutics; agents targeting distinct components of the immune/inflammatory response; and novel small molecules that block the actions of RAGE (receptor for advanced glycation end products) signaling, also hold potential as new therapies for diabetes mellitus and cardiovascular disease.
|
30786741 |
2019 |
|
Cardiovascular Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Receptor for advanced glycation end products (RAGE) is a multiligand receptor belonging to the immunoglobulin superfamily and plays crucial roles in the development of many human diseases such as neurodegenerative diseases, diabetes, cardiovascular diseases, osteoarthritis and cancer.
|
29477598 |
2018 |
|
Cardiovascular Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
These results demonstrated a potential role of monocyte adhesion, chemotaxis, and macrophage polarization in the development cardiovascular diseases induced by IH and identified that RAGE could be a promising therapeutic target to prevent atherosclerosis in patients with OSA.
|
30402462 |
2018 |
|
Cardiovascular Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease.
|
28864204 |
2017 |
|
Cardiovascular Diseases
|
0.300 |
AlteredExpression
|
group |
BEFREE |
Second, AGEs interaction with their major cell surface signal transduction receptor for AGE or RAGE sets off a cascade of events leading to modulation of gene expression and loss of vascular and tissue homeostasis, processes that contribute to cardiovascular disease.
|
29259621 |
2017 |
|
Cardiovascular Diseases
|
0.300 |
GeneticVariation
|
group |
BEFREE |
This study aimed to investigate whether RAGE gene polymorphisms are associated with the prognosis of various cardiovascular diseases in the Chinese Han population.
|
28660308 |
2017 |
|
Cardiovascular Diseases
|
0.300 |
GeneticVariation
|
group |
BEFREE |
We investigated whether the functional polymorphism in the promoter region of the RAGE gene (-374 T/A) influences development of cardiovascular disease in the end-stage renal disease (ESRD) patients.
|
26429324 |
2015 |
|
Cardiovascular Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
In recent years the role of AGEs in the pathogenesis of cardiovascular diseases has become recognized but little is known about the role of the AGERAGE system in heart failure.
|
23527722 |
2013 |
|
Cardiovascular Diseases
|
0.300 |
Biomarker
|
group |
RGD |
Glucose degradation products result in cardiovascular toxicity in a rat model of renal failure.
|
20056977 |
2011 |
|
Cardiovascular Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
The role of RAGE in the pathogenesis of cardiovascular disease in diabetic patients requires further study.
|
20040351 |
2010 |
|
Cardiovascular Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Intra-coronary sRAGE administration attenuates RAGE-mediated myocardial fibrosis and I/R injury through a TGF-beta1-dependent mechanism, suggesting a clinical potential in treating RAGE/ligand-associated cardiovascular diseases.
|
20367988 |
2010 |
|
Cardiovascular Diseases
|
0.300 |
Biomarker
|
group |
BEFREE |
Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
|
18089449 |
2008 |
|
Cardiovascular Diseases
|
0.300 |
GeneticVariation
|
group |
LHGDN |
Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
|
17224333 |
2007 |
|
Cardiovascular Diseases
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Further studies are required on other more prevalent genetic variants of RAGE and cardiovascular disease.
|
16159602 |
2005 |
|
Cardiovascular Diseases
|
0.300 |
GeneticVariation
|
group |
BEFREE |
The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.
|
12606536 |
2003 |
|
Cardiovascular Diseases
|
0.300 |
GeneticVariation
|
group |
LHGDN |
The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients.
|
12606536 |
2003 |